Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita

January 8, 2021

Kidney care innovators Renalytix AI and DaVita are partnering on a new program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). This first of its kind program is expected to improve patient outcomes and provide meaningful cost reductions for healthcare providers and payors by enabling earlier intervention for patients with early-stage kidney disease (stages 1, 2 and 3) through actionable risk assessments and end-to-end care management.

The collaboration is expected to launch in three major markets this year. As the program expands, DaVita and RenalytixAI intend to pursue risk-sharing arrangements with healthcare providers and payors to drive kidney disease patient care innovation, cost efficiencies and improve quality of life.

“This is the first clinical-grade program that delivers advanced early-stage prognosis and risk stratification, combined with actionable care management right to the primary care level where the majority of kidney disease patients are being seen,” said James McCullough, RenalytixAI Chief Executive Officer. “Making fundamental change in kidney disease health economics and outcomes must begin with providing a clear, actionable understanding of disease progression risk.”

“Almost 50% of people whose kidneys fail find out after it is too late, and we are on a mission to change that,” said Javier Rodriguez, Chief Executive Officer for DaVita.

The program utilizes the KidneyIntelX in vitro diagnostic platform from RenalytixAI, which uses a machine learning algorithm to assess a combination of biomarkers from a simple blood draw with features from the electronic health record to generate a patient-specific risk score.